We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




First Of Its Kind Measles Antibody Test Validated for Use with Dried Blood Spot Samples

By LabMedica International staff writers
Posted on 04 Mar 2025
Print article
Image: The Anti-Measles Virus ELISA 2.0 (IgG) has received CE Mark (Photo courtesy of AdobeStock)
Image: The Anti-Measles Virus ELISA 2.0 (IgG) has received CE Mark (Photo courtesy of AdobeStock)

Measles is a highly contagious airborne disease that can lead to serious complications for those infected. With the number of measles cases increasing worldwide, expanding and improving access to testing for the measles virus is crucial for enhancing surveillance and prevention efforts. Now, a novel assay supports the diagnosis of a measles virus infection and also determines the immune status against measles virus, with validation for dried blood spots (DBS) as well as serum and plasma samples.

Revvity, Inc. (Waltham, MA, USA) has launched EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG), designed to assist in diagnosing measles virus infections or determining immunity to the virus. The Anti-Measles Virus ELISA 2.0 (IgG) is the first in a series of assays being developed by EUROIMMUN to expand its portfolio of serological infection diagnostics, now including validation for DBS in addition to serum and plasma. The use of DBS in diagnostics only requires a few drops of capillary blood to produce reliable test results. The blood is typically obtained from the fingertip, placed on a paper card, and then sent to a diagnostic lab for analysis.

The minimally invasive sampling method and the high stability of DBS make this diagnostic approach advantageous for routine testing, research studies, or in areas with limited medical infrastructure. By enabling the use of DBS rather than traditional venous blood samples, this innovation increases accessibility for healthcare practitioners and diagnostic labs investigating measles virus infections. The Anti-Measles Virus ELISA 2.0 (IgG) can be processed either manually or automatically with EUROIMMUN’s scalable solutions designed for DBS processing and ELISA.

“Because there was no commercial assay for detecting anti-measles virus IgG antibodies using a DBS sample, diagnostic laboratories have had to validate DBS on their own. Now we can fill this gap by offering an IVDR-compliant solution,” said Dr. Lars Komorowski, chief scientific officer of EUROIMMUN.

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Refrigerated Microtube Homogenizer
BeadBlaster 24R
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA

Print article

Channels

Immunology

view channel
Image: New research has revealed a novel biomarker for autoimmune diseases (Photo courtesy of Shutterstock)

Novel Analytical Method Tracks Progression of Autoimmune Diseases

Patients with autoimmune diseases often have lifelong contact with doctors and hospitals. The typical patient diagnosed is a woman in her fifties and the disease requires lifelong treatment.... Read more

Microbiology

view channel
Image: The study identified a genetic signature in bacteria that, when present, indicates the likelihood of developing antibiotic resistance (Photo courtesy of Tulane University)

Unique Genetic Signature Predicts Drug Resistance in Bacteria

Antibiotic resistance represents a significant global health threat, responsible for over a million deaths each year. By 2050, the World Health Organization predicts that it could surpass cancer and heart... Read more

Pathology

view channel
Image: The squares are representative partial pictures from the cancer microscopy slides, that the AI system has automatically organized by their similarity (Photo courtesy of University of Jyväskylä)

New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis

Tissue analysis typically involves a pathologist reviewing scanned digital slides from a patient’s intestinal sample and marking specific areas, such as those where cancerous and related tissues are present.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.